To further elucidate the anti-tumor effect of the combination treatment of P-IL-2 and Palbociclib, spleens and tumor tissues were subjected to flow cytometry measurements to observe the changes in the tumor immune microenvironment. The gene discussed is IL2; the disease is neoplasm.